Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

Christophe Fermé, Houchingue Eghbali, Jacobus H. Meerwaldt, Chantal Rieux, Jacques Bosq, Françoise Berger, Théodore Girinsky, Pauline Brice, Mars B. Van'T Veer, Jan A. Walewski, Pierre Lederlin, Umberto Tirelli, Patrice Carde, Eric Van Den Neste, Emmanuel Gyan, Mathieu Monconduit, Marine Diviné, John M M Raemaekers, Gilles Salles, Evert M. NoordijkGeert Jan Creemers, Jean Gabarre, Anton Hagenbeek, Oumédaly Reman, Michel Blanc, José Thomas, Brigitte Vié, Johanna C. Kluin-Nelemans, Fernando Viseu, Joke W. Baars, Philip Poortmans, Pieternella J. Lugtenburg, Christian Carrie, Jérôme Jaubert, Michel Henry-Amar

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year eventfree survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P

Original languageEnglish
Pages (from-to)1916-1927
Number of pages12
JournalNew England Journal of Medicine
Volume357
Issue number19
DOIs
Publication statusPublished - Nov 8 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease'. Together they form a unique fingerprint.

Cite this